Analyses of peripheral blood samples from cases of CLL confirmed that CD19+ B cells with the malignant CD5+ phenotype, which predominate in patients’ PBMC, had low levels of CD22, and their expression of Siglec‐10 was also found to be somewhat reduced (Figure S4b). This evidence concerns the gene CD5 and B-cell chronic lymphocytic leukemia.